- London
- Director
Provides scientific and medical expertise at study level across early- and late-phase hepatology assets, serving as medical monitor for Phase 1–4 trials and leading protocol, IB, ICF and CSR authoring. Works within cross-functional global study teams and the Clinical Matrix Team, integrating efficacy, safety and biomarker data to inform asset and portfolio decisions, with informal coaching of less experienced clinical scientists.